吉林秉责律师事务所 本次股东会由公司董事会召集，会议召开方式为现场投票与网络投票相结合 的方式。 1 关于通化东宝药业股份有限公司 二 0 二五年第三次临时股东会的法律意见书 致：通化东宝药业股份有限公司 根据《中华人民共和国证券法》（以下简称"证券法"）、《中华人民共和国 公司法》（以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规 则》）和《通化东宝药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，吉林秉责律师事务所（以下简称"本所"）接受了通化东宝药业股份有限公 司（以下简称"公司"）的委托，担任公司 2025 年第三次临时股东会（以下简称 "本次股东会"）特聘专项法律顾问并出具法律意见书。 本法律意见书仅供公司为本次股东会之目的而使用，不得用于其他任何目 的。本所同意公司将本法律意见书作为本次股东会的公告材料，随其他需要公告 的信息一起向公众披露，并依法对本所在其中发表的法律意见承担责任。 为出具本法律意见书，本所指派郭淑芬、商家碧律师出席了公司于 2025 年 11 月 3 日上午 10 时在公司会议室召开的本次股东会，审查了公司提供的与召开 本次股东会有关的文件和资料，并进 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-076 通化东宝药业股份有限公司 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 3 日 (二)股东会召开的地点：公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 599 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 881,399,412 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 45.1362 | 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，公司董事长李佳鸿先生主持会议。会议采用现 场投票和网络投票相结合的表决方式。本次会议的召集、召开符合《公司法》和 《公司章程》的有关规定。 1 (五) ...

Core Viewpoint - The controlling shareholder, Dongbao Group, has announced a share buyback plan for Tonghua Dongbao Pharmaceutical Co., Ltd., expressing confidence in the company's future development and value recognition [1][2]. Summary by Sections Share Buyback Plan - Dongbao Group plans to increase its shareholding in Tonghua Dongbao starting from October 31, 2024, through centralized bidding on the Shanghai Stock Exchange, with a minimum increase of 1% of the total share capital (19,817,341 shares) and a maximum of 2% (39,634,681 shares) [1]. - The implementation period for the buyback plan is from October 31, 2024, to October 30, 2025, without a set price range, depending on stock price fluctuations and overall market trends [1]. Implementation Results - As of October 30, 2025, Dongbao Group has successfully increased its shareholding by 27,801,409 shares, amounting to 228 million yuan, which represents 1.42% of the current total share capital [2]. - The actual increase has exceeded the lower limit of the buyback plan [2]. Additional Information - The buyback plan complies with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange listing rules [3]. - The implementation of this buyback plan will not affect the company's shareholding structure or lead to changes in the controlling shareholder [4].

Core Viewpoint - Tonghua Dongbao is a leading company in the domestic insulin industry, with a strong performance in revenue and net profit, showcasing its competitive advantages in the market [1][2]. Group 1: Business Performance - In Q3 2025, Tonghua Dongbao achieved a revenue of 2.18 billion yuan, ranking 5th among 34 companies in the industry, surpassing the industry average of 1.26 billion yuan and the median of 734 million yuan [2]. - The net profit for the same period was 1.188 billion yuan, the highest in the industry, exceeding the average of 166 million yuan and the median of 56.63 million yuan [2]. Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 12.46%, an increase from 9.74% year-on-year, but still below the industry average of 26.88%, indicating strong solvency [3]. - The gross profit margin for Q3 2025 was 71.89%, down from 74.47% year-on-year, yet still above the industry average of 70.17%, reflecting good profitability [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.08% to 82,100, while the average number of circulating A-shares held per account increased by 5.35% to 23,800 [5]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked third with 35.8443 million shares, an increase of 15.839 million shares from the previous period [5]. Group 4: Business Highlights - The company reported that in Q3 2025, revenue from insulin analogs surpassed that of second-generation human insulin for the first time, with an expected 40% growth in insulin sales for the year [6]. - The company is expanding its international presence, with its Aspart insulin having received BLA acceptance in the U.S. and insulin analogs approved for sale in Myanmar and Indonesia [6].

Group 1 - The QFII system has become a significant channel for foreign capital to enter the A-share market since its introduction in 2002, with distinct stock selection preferences and investment styles compared to domestic funds [1][8] - In the third quarter, at least 121 stocks were increased in holdings by QFII, with the most significant increases not in the semiconductor sector but in electrical equipment, machinery, hardware, and chemicals [2][3] - Major QFII institutions like Morgan Stanley and Abu Dhabi Investment Authority have continued to increase their positions in A-shares, with a focus on a diversified portfolio of stocks [1][2] Group 2 - The top five industries with the most significant QFII increases in holdings in the third quarter were machinery, hardware equipment, electrical equipment, semiconductors, and chemicals [2] - Notably, only one stock from the banking sector, Nanjing Bank, was among the top 20 stocks increased by QFII, with a significant increase of 124 million shares by BNP Paribas [4] - Abu Dhabi Investment Authority has a concentrated investment style, holding only 22 stocks, and has made selective increases and decreases in its holdings, including a notable reduction in its stake in Zijin Mining [5][6] Group 3 - The GATES FOUNDATION TRUST has a concentrated portfolio with a preference for small-cap stocks, holding only two stocks at the end of the third quarter [6] - The Macau Monetary Authority has been active in increasing its holdings, particularly in the non-ferrous metals, food and beverage, and automotive sectors [7] - The QFII system is expected to expand further, with over 900 qualified foreign investors and ongoing reforms aimed at making it easier for foreign investors to participate in the Chinese market [8]

证券代码：600867 证券简称：通化东宝 公告编号：2025-075 通化东宝药业股份有限公司 关于控股股东增持公司股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况：通化东宝药业股份有限公司（以下简称"公司"、 "通化东宝"）于 2024 年 10 月 30 日收到控股股东东宝实业集团股份有限公司（以 下简称"东宝集团"）增持股份计划的通知。基于对公司未来发展前景的信心和 对公司价值的高度认可，控股股东东宝集团计划自 2024 年 10 月 31 日起，通过 上海证券交易所以集中竞价交易方式增持公司股份。本次增持比例不低于公司总 股本 1%，即 19,817,341 股，不超过公司总股本 2%，即 39,634,681 股。若增持 计划实施期间，公司发生有送股、资本公积金转增股本、股份回购注销等股份变 动事项，则对增持数量进行相应调整。实施期限为自 2024 年 10 月 31 日之日起 12 个月内（即 2024 年 10 月 31 日至 2025 年 10 月 3 ...

关于通化东宝药业股份有限公司 控股股东增持公司股份的 法律意见书 致：通化东宝药业股份有限公司 吉林秉责律师事务所(以下简称"本所")接受通化东宝药业股份 有限公司（以下简称"通化东宝"或"公司"）的委托，指派本所律 师对公司控股股东东宝实业集团股份有限公司（以下简称"东宝集 团"）增持公司股份（以下简称"本次增持"）事宜实施专项核查并 出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证 券法》"）《律师事务所从事证券法律业务管理办法》和《律师事务 所证券法律业务执业规则（试行）》等规定及本法律意见书出具日以 前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责 和诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定 的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在 虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 吉林秉责律师事务所 （一）增持主体的基本情况 本次增持的增持主体为公司控股股东东宝集团，本所律师核查， 截至本法律意见书出具之日，增持主体的基本情况如下： 本法律意见书根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《证券法》《上市 ...

Core Viewpoint - Tonghua Dongbao announced a share buyback plan, reflecting confidence in the company's future development and recognition of its value [1] Group 1: Share Buyback Details - The company plans to repurchase a total of 27.8014 million shares, which represents 1.42% of the current total share capital [1] - The total amount allocated for the buyback is approximately 228.0059 million yuan [1] - Following the buyback, the shareholding ratio of Dongbao Group and its concerted parties will increase from 31.06% to 32.75% [1] Group 2: Implementation and Control - The buyback plan has been fully implemented without causing any changes in the company's controlling shareholder or actual controller [1]

Summary of Key Points Core Viewpoint - As of October 30, 4271 companies have released their Q3 2025 reports, with 2318 companies showing year-on-year profit growth, while 1953 companies reported a decline. Additionally, 2534 companies experienced revenue growth, and 1737 companies saw a decrease. Notably, 1768 companies had both profit and revenue growth, while 1187 companies reported declines in both metrics. There are 547 companies with profit growth exceeding 100%, with Fangzheng Electric showing the highest increase at 153128.60% [1]. Financial Performance Overview - **Profit Growth**: 2318 companies reported a year-on-year increase in net profit, while 1953 companies experienced a decline [1]. - **Revenue Growth**: 2534 companies saw an increase in operating revenue, whereas 1737 companies reported a decrease [1]. - **Simultaneous Growth**: 1768 companies had both net profit and operating revenue growth, indicating a positive trend in performance for a significant number of firms [1]. - **Decline in Performance**: 1187 companies reported declines in both net profit and operating revenue, highlighting potential challenges faced by these firms [1]. Notable Companies - **Fangzheng Electric**: Achieved the highest net profit growth of 153128.60% with a net profit of 1375.73 million and operating revenue of 201253.53 million [1]. - **Jingrui Materials**: Reported a net profit of 12836.85 million with a year-on-year growth of 19202.65%, and operating revenue growth of 118684.44% [1]. - **Hengyu Environmental**: Showed a net profit of 1446.17 million, with a significant year-on-year growth of 17879.81% and operating revenue growth of 191.99% [1]. - **ST Weier**: Reported a net profit of 19534.45 million with a year-on-year increase of 15294.42% and operating revenue growth of 6.44% [1]. Additional Insights - Companies like Nanji Light and Huahong Technology also reported substantial growth in both net profit and operating revenue, indicating a robust performance in certain sectors [1]. - The data reflects a mixed performance across various industries, with some companies thriving while others face declines, suggesting a diverse landscape in the current market [1].

Core Insights - QFII continues to favor core A-share assets, particularly in high-end manufacturing and defensive sectors, reflecting a strategic approach to investment amidst ongoing market trends [1][2][7] - As of October 28, nearly 40 QFIIs collectively held approximately 119.4 billion yuan in A-shares, indicating significant foreign interest in the Chinese market [1][9] Industry Focus - QFII has notably increased holdings in various sectors, including banking, electrical equipment, building materials, chemicals, software services, machinery, and hardware [3][10] - The banking sector saw a substantial increase, with QFII adding 124 million shares, driven by expectations of improved performance and attractive valuations [7][10] - Electrical equipment and computer sectors also received tactical increases from QFII, supported by favorable policies and growth in demand due to energy transition and infrastructure upgrades [7][10] Notable Stocks - Key stocks with significant QFII increases include Nanjing Bank (12.36 million shares), China Western Power (7.29 million shares), and others in various sectors such as construction materials and chemicals [6][10] - Specific stocks like Huazhi Technology and Huasheng Tiancheng saw multiple QFII firms increase their stakes, indicating strong interest in new productivity concepts [4][5] Investment Strategy - QFII's investment strategy appears to be diversified, focusing on both core assets and emerging opportunities across multiple industries, including machinery, food and beverage, and pharmaceuticals [10][11] - Large foreign institutions, such as Goldman Sachs, are actively seeking diversified investment opportunities in the A-share market, reflecting a positive outlook on Chinese equities [11][12]